267 related articles for article (PubMed ID: 15965198)
1. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
Ravina B; Putt M; Siderowf A; Farrar JT; Gillespie M; Crawley A; Fernandez HH; Trieschmann MM; Reichwein S; Simuni T
J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):934-9. PubMed ID: 15965198
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Leroi I; Brandt J; Reich SG; Lyketsos CG; Grill S; Thompson R; Marsh L
Int J Geriatr Psychiatry; 2004 Jan; 19(1):1-8. PubMed ID: 14716693
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
6. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
Aarsland D; Laake K; Larsen JP; Janvin C
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):708-12. PubMed ID: 12023410
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Black S; Román GC; Geldmacher DS; Salloway S; Hecker J; Burns A; Perdomo C; Kumar D; Pratt R;
Stroke; 2003 Oct; 34(10):2323-30. PubMed ID: 12970516
[TBL] [Abstract][Full Text] [Related]
8. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG
Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
10. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
Stryjer R; Strous RD; Bar F; Werber E; Shaked G; Buhiri Y; Kotler M; Weizman A; Rabey JM
Clin Neuropharmacol; 2003; 26(1):12-7. PubMed ID: 12567159
[TBL] [Abstract][Full Text] [Related]
12. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
Prasher VP; Huxley A; Haque MS;
Int J Geriatr Psychiatry; 2002 Mar; 17(3):270-8. PubMed ID: 11921156
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
[TBL] [Abstract][Full Text] [Related]
14. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Courtney C; Farrell D; Gray R; Hills R; Lynch L; Sellwood E; Edwards S; Hardyman W; Raftery J; Crome P; Lendon C; Shaw H; Bentham P;
Lancet; 2004 Jun; 363(9427):2105-15. PubMed ID: 15220031
[TBL] [Abstract][Full Text] [Related]
15. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
Rogers SL; Friedhoff LT
Dementia; 1996; 7(6):293-303. PubMed ID: 8915035
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
Cummings JL
J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):903-4. PubMed ID: 15965192
[No Abstract] [Full Text] [Related]
18. Donepezil: in vascular dementia.
Goldsmith DR; Scott LJ
Drugs Aging; 2003; 20(15):1127-36. PubMed ID: 14651435
[TBL] [Abstract][Full Text] [Related]
19. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.
Winblad B; Engedal K; Soininen H; Verhey F; Waldemar G; Wimo A; Wetterholm AL; Zhang R; Haglund A; Subbiah P;
Neurology; 2001 Aug; 57(3):489-95. PubMed ID: 11502918
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study.
Mori E; Ikeda M; Iseki E; Katayama S; Nagahama Y; Ohdake M; Takase T
Psychogeriatrics; 2024 May; 24(3):542-554. PubMed ID: 38439118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
